Menatetrenone
MUSCULO-SKELETAL SYSTEM
Also known as: Menaquinone 4, vitamin k2, Vitamin MK 4
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Menatetrenone is a drug catalogued in DrugCentral. DrugCentral lists 2 molecular targets, including SNCA and Cruzipain. Recorded indications include Hemorrhagic disease of the newborn due to vitamin K deficiency.
- Molecular targets: SNCA and Cruzipain (2 listed in DrugCentral).
- Indications: Hemorrhagic disease of the newborn due to vitamin K deficiency.
- ATC code: M05BX08 (Other drugs affecting bone structure and mineralization).
- Molecular formula: C31H40O2; molecular weight 444.66 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Hemorrhagic disease of the newborn due to vitamin K deficiency
Mechanism & targets
Molecular targets (2)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Alpha-synuclein | SNCA | unknown | IC50 4.82 |
| Cruzipain | — | unknown | IC50 4.74 |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
M05BX08 | MUSCULO-SKELETAL SYSTEM › DRUGS FOR TREATMENT OF BONE DISEASES › DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION › Other drugs affecting bone structure and mineralization |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Cerebral haemorrhage | 85.4 |
| Cerebral infarction | 78.7 |
| Hepatic function abnormal | 77.8 |
| Disseminated intravascular coagulation | 56.9 |
| Platelet count decreased | 51.4 |
| Brain herniation | 39.9 |
| Renal impairment | 37.9 |
| Thalamus haemorrhage | 37.7 |
| Intraventricular haemorrhage | 35.3 |
| Altered state of consciousness | 32.1 |
| Embolic stroke | 31.7 |
| Upper respiratory tract inflammation | 29.8 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Menatetrenone is on its molecule page.
| Molecular formula | C31H40O2 |
|---|---|
| Molecular weight | 444.66 g/mol |
| CAS number | 863-61-6 |
| InChIKey | DKHGMERMDICWDU-GHDNBGIDSA-N |
| PubChem CID | 5282367 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Menatetrenone used for?
DrugCentral lists the following indications for Menatetrenone: Hemorrhagic disease of the newborn due to vitamin K deficiency.
How does Menatetrenone work?
Its molecular targets in DrugCentral include SNCA and Cruzipain.
What is the chemical formula of Menatetrenone?
Menatetrenone has the molecular formula C31H40O2 and a molecular weight of 444.66 g/mol.
Browse: all drugs starting with M · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 1685 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL259223 — compound record and bioactivity
- PubChem CID 5282367 — chemical identifiers
- DrugBank DB12148 — drug record
- FDA UNII 27Y876D139 — substance identity
- UniProt P37840 (SNCA) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.